

Nona Chamankhah, PharmD, BCIDP, BCPS

Research Summary

Dr. Chamankhah is a lecturer at Skaggs School of Pharmacy and Pharmaceutical Sciences, and holds the position of Health Sciences Affiliate Faculty, Non-Salaried. She is also a Clinical Pharmacist at Rady Children's Hospital and serves as a leader for the Infectious Disease Preceptor and Medicine Preceptor. She is the Conference Chair for SPPS 212C Therapeutics course and gives lectures for a variety of courses. Prior to this, she held an internship at Kaiser Permanente in South San Francisco.

Academic Achievements

McGill University, B.S. in Biochemistry (2012), University of California San Francisco, Doctor of Pharmacy (2016), University of California San Diego, Post-Graduate Year 1 (PGY-1) Acute Care Pharmacy Residency (2017), University of California San Diego, Post-Graduate Year 2 (PGY2) Infectious Diseases Pharmacy Residency (2018).

Teaching

Therapeutics (SPPS 212C)

Key Contributions

Rady Children's Hospital House Staff of the Year (2020), UC San Francisco School of Pharmacy Dean's Pathway Project Award (2016), UC San Francisco CHIH Foundation Research and Publication Award (2016), UC San Francisco School of Pharmacy Global Health Grant (2015), UC San Francisco Pharmacy Pathway Project Grant (2015), UC San Francisco Apple Excellence in Student Teaching Award (2015), UC San Francisco Apple Excellence in Student Teaching Award (2014), UC San Francisco Alumni Scholarship (2014), McGill Distinction and First Class Graduation Honors (2012), McGill Dean's Honor List (2009).

Selected Publications

- Whalen M, Kajubi R, Chamankhah N, Huang L, Orukan F, et al. Reduced exposure to piperazine, compared to adults, in young children, receiving dihydroartemisinin-piperazine as malaria chemoprevention. *Clinical Pharmacology & Therapeutics* 2019; 106(6): 1310-1318.
- Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, et al. Antiretroviral therapy with efavirenz accentuates pregnancy-associated reduction of dihydroartemisinin-piperazine exposure during malaria chemoprevention. *Clinical Pharmacology & Therapeutics* 2017; 102(3): 520-528.